MedTrace Logo

Add-on Clioquinol in Drug-resistant Childhood Epilepsy: an Exploratory Study

NCT05727943 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-02-14

No results posted yet for this study

Summary

In this exploratory trial, the potential anti-seizure activity of clioquinol in a small cohort of adolescents with drug-resistant epilepsy will be examined. Subjects will be exposed to clioquinol add-on for a period of maximum 8 weeks (2 weeks low dose, 6 weeks higher dose). The main hypothesis of the study is that 30% of the included subjects will be responders and that the median seizure frequency reduction will be at least 30%.

Conditions

  • Epilepsy Intractable

Interventions

DRUG

Clioquinol

add on clioquinol to concomitant ASM

Sponsors & Collaborators

  • KU Leuven

    lead OTHER

Principal Investigators

  • Lieven Lagae, MD PhD · University Hospitals, University of Leuven

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05727943 on ClinicalTrials.gov